Pomerantz Law Firm Launches Investigation into Unicycive Therapeutics for Potential Securities Fraud

Investor Alert: Pomerantz Law Firm Investigates Unicycive Therapeutics Inc.

Pomerantz LLP, a reputable law firm based in New York, has initiated an investigation focusing on claims against Unicycive Therapeutics, Inc., trading under the NASDAQ symbol UNCY. Investors who may have suffered losses are encouraged to reach out to the firm for consultation and potential class action participation.

On June 30, 2025, Unicycive made headlines with its press release revealing concerning news regarding its drug application to the U.S. Food and Drug Administration (FDA). The FDA issued a Complete Response Letter (CRL) for Unicycive’s New Drug Application (NDA) intended for treating hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. This unexpected development caused a significant ripple effect in the market, with Unicycive's stock plunging by $2.03, which translates to a staggering 29.85% drop. The closing share price hit $4.77, raising eyebrows about potential underlying issues within the company.

The core of this investigation revolves around the possibility that Unicycive Therapeutics, along with certain officials and directors, may have been involved in securities fraud or unethical business practices. The alarming drop in stock price following the FDA announcement prompts a closer look into the company’s operational and compliance standards. Specifically, the FDA pointed out deficiencies related to a third-party manufacturing vendor associated with the company's contract development and manufacturing organization, which could have implications on the drug's approval process and, ultimately, the company's financial health.

Founded by renowned attorney Abraham L. Pomerantz, known for pioneering class action litigation, Pomerantz LLP has built a strong reputation in corporate, securities, and antitrust law. The firm has helped numerous clients recover substantial damages in similar securities fraud cases. Their commitment to upholding investors' rights and ensuring accountability strikes a chord in today's volatile market environment, where misinformation or negligence can lead to devastating outcomes for shareholders.

As the investigation unfolds, investors are reminded of their rights to seek recourse for any financial losses incurred during their investment in Unicycive Therapeutics. Pomerantz encourages affected shareholders to connect with their legal team for potential class-action opportunities, urging investors who suffered losses to come forward, share their experiences and join the ongoing pursuit of justice against corporate malpractice.

Pomerantz LLP maintains a presence in major financial cities worldwide, including Chicago, Los Angeles, London, Paris, and Tel Aviv, advocating for investors who may have experienced losses due to deceptive practices. If you are an investor in Unicycive Therapeutics or have further questions regarding the ongoing investigation, please do not hesitate to contact Danielle Peyton at [email protected] or by phone at 646-581-9980, ext. 7980.

In a financial landscape increasingly marked by scrutiny and regulatory oversight, this investigation underscores the necessity for transparency in corporate governance and affirming investors’ trust in the systems designed to protect their investments.